NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/08/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization10,432 mln
Float192 mln
Earnings Date08/04/2026
EPS
1.39
Stretched
P / E
38.89
Overvalued
Piotroski F-Score
5
/ 9
Neutral
Beneish M-Score
-2.49
Borderline
1-Year Forecast
90.12
Transformational upside
Relative Strength
60
/ 100
Outperforming
Business Description
BioMarin is a California-based biotechnology company founded in 1996 that creates and sells treatments for rare, life-threatening diseases across markets in the US, Europe, Latin America, the Middle East, Asia Pacific, and beyond. Its portfolio includes several approved medicines targeting conditions such as certain bone growth disorders, inherited metabolic diseases, and enzyme deficiencies, along with a pipeline of new treatments in development. The company sells its products through specialty pharmacies, hospitals, distributors, and government agencies worldwide.
